Evoke Pharma Inc (EVOK) - Total Assets
Based on the latest financial reports, Evoke Pharma Inc (EVOK) holds total assets worth $15.65 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Evoke Pharma Inc - Total Assets Trend (2011–2024)
This chart illustrates how Evoke Pharma Inc's total assets have evolved over time, based on quarterly financial data. Also see Evoke Pharma Inc market cap and net worth for the company's overall valuation and market capitalisation.
Evoke Pharma Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Evoke Pharma Inc's total assets of $15.65 Million consist of 98.4% current assets and 1.6% non-current assets. Review total liabilities of Evoke Pharma Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 77.6% |
| Accounts Receivable | $2.42 Million | 13.8% |
| Inventory | $445.08K | 2.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Evoke Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Evoke Pharma Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Evoke Pharma Inc's current assets represent 98.4% of total assets in 2024, a decrease from 100.0% in 2011.
- Cash Position: Cash and equivalents constituted 77.6% of total assets in 2024, down from 95.6% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 13.8% of total assets.
Evoke Pharma Inc Competitors by Total Assets
Key competitors of Evoke Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Evoke Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.27 | 1.44 | 1.23 |
| Quick Ratio | 1.22 | 1.39 | 1.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.30 Million | $4.27 Million | $1.75 Million |
Evoke Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Evoke Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.64 |
| Latest Market Cap to Assets Ratio | 1.08 |
| Asset Growth Rate (YoY) | 147.8% |
| Total Assets | $17.52 Million |
| Market Capitalization | $18.95 Million USD |
Valuation Analysis
Above Book Valuation: The market values Evoke Pharma Inc's assets above their book value (1.08x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Evoke Pharma Inc's assets grew by 147.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Evoke Pharma Inc (2011–2024)
The table below shows the annual total assets of Evoke Pharma Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $17.52 Million | +147.84% |
| 2023-12-31 | $7.07 Million | -40.36% |
| 2022-12-31 | $11.85 Million | +12.09% |
| 2021-12-31 | $10.57 Million | +12.07% |
| 2020-12-31 | $9.43 Million | +47.51% |
| 2019-12-31 | $6.40 Million | +13.00% |
| 2018-12-31 | $5.66 Million | -28.73% |
| 2017-12-31 | $7.94 Million | -14.55% |
| 2016-12-31 | $9.29 Million | -2.50% |
| 2015-12-31 | $9.53 Million | -37.70% |
| 2014-12-31 | $15.30 Million | -38.76% |
| 2013-12-31 | $24.99 Million | +21437.64% |
| 2012-12-31 | $116.01K | -87.19% |
| 2011-12-31 | $905.34K | -- |
About Evoke Pharma Inc
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medi… Read more